NCT07298759Completed
The Effect of Hydroxytyrosol Administration on Superoxide Dismutase, Pulsatility Index and Resistance Index of Uterine Artery Doppler and Flow-Mediated Dilatation of Brachial Artery In Mothers With Hypertension In Pregnancy
The Effect of Hydroxytyrosol Administration on Superoxide Dismutase, Pulsatility Index and Resistance Index of Uterine Artery Doppler and Flow-Mediated Dilatation of Brachial Artery In Mothers With Hypertension In Pregnancy: A Randomized Double Blind Controlled Trial
Source: ClinicalTrials.gov · Last updated 26 Aug 2026
Brief summary (registry, in English)
The purpose of this clinical trial is to evaluate the effect of hydroxytyrosol 10 mg/day administered for 4 weeks in pregnant individuals with hypertension. This study will assess whether hydroxytyrosol increases serum superoxide dismutase levels, reduces uterine artery Doppler pulsatility and resistance indices, and improves brachial artery flow-mediated dilation. Participants will be randomly assigned to receive either hydroxytyrosol or a matching placebo. Both products will be visually identical to ensure blinding. Participants will take two capsules daily for 4 weeks and attend two study visits for assessments and follow-up.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 52 (actual)
- First submitted
- 24 Jul 2025
- Start date
- 11 Jun 2025
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Dr Cipto Mangunkusumo General Hospital
- Diseases
- High blood pressure
- NCT number
- NCT07298759
What you commit to
- Study type: Interventional
- Participants enrolled: 52
- From 11 Jun 2025 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Pregnancy with infection, including chronic infections such as tuberculosis (TB), HIV, or hepatitis B
- Pregnancy with other complications (e.g., diabetes mellitus, heart disease, kidney disease, liver disease, malignancy, autoimmune disorders)
Other
- Refusal to participate in the study
Who the study is looking for
- Singleton pregnancy with a live intrauterine fetus
- Gestational age 24-32 weeks. Gestational age is confirmed based on:
- Last Menstrual Period (LMP)
- First trimester ultrasound biometry
- Belongs to the Hypertensive Disorders of Pregnancy group, with the following criteria:
- Gestational hypertension and preeclampsia according to ACOG 2018 criteria
- Chronic hypertension according to ACOG 2019 criteria
- Superimposed preeclampsia according to ACOG 2018 criteria
Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dr. Cipto Mangunkusumo National Central Public Hospital Coordinator of this site? Confirm its status | Jakarta | Indonesia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.